Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Osteocalcin levels decrease during the treatment of an acute depressive episode

E. Bartečků, J. Hořínková, P. Křenek, A. Damborská, J. Tomandl, M. Tomandlová, J. Kučera, J. Fialová Kučerová, J. Bienertová-Vašků

. 2022 ; 13 (-) : 893012. [pub] 20220802

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023609

Objectives: Osteocalcin is a protein secreted by osteoblasts with a versatile endocrine role. Several domains in which it plays a role-stress response, monoamine synthesis, and cognitive functioning-are implicated also in the pathophysiology of major depressive disorder. In search of possible objective biomarkers of depression, the aim of the study was to assess the relationship between osteocalcin and depressive symptoms during the treatment of depressive episode. Methods: The study included female inpatients with at least moderate depressive episode. In these patients, depression severity was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS), and osteocalcin levels were assessed before the stabilization of antidepressive treatment and after 6 weeks. Relationships between osteocalcin levels and symptoms were analyzed with mixed-effect and linear models, taking into account age, menopausal status, and body mass index. Results: In 11 out of 13 enrolled inpatients, osteocalcin levels decreased during the first 6 weeks of treatment; this decrease was significant according to the mixed-effects model (t = -2.345, p = 0.019). According to the linear model, this decrease was significantly associated with reduction in depressive symptom severity (t = 2.673, p = 0.028). Osteocalcin was not associated with initial depressive symptom severity, and initial osteocalcin levels did not predict response to treatment. Limitations of the study include low sample size and inclusion of both pre- and postmenopausal women of various ages. Conclusions: This preliminary study suggests that osteocalcin may be a candidate biomarker of antidepressive treatment response and that this topic warrants further investigation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023609
003      
CZ-PrNML
005      
20230220151544.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fpsyt.2022.893012 $2 doi
035    __
$a (PubMed)35982931
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bartečků, Elis $u Department of Psychiatry, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia
245    10
$a Osteocalcin levels decrease during the treatment of an acute depressive episode / $c E. Bartečků, J. Hořínková, P. Křenek, A. Damborská, J. Tomandl, M. Tomandlová, J. Kučera, J. Fialová Kučerová, J. Bienertová-Vašků
520    9_
$a Objectives: Osteocalcin is a protein secreted by osteoblasts with a versatile endocrine role. Several domains in which it plays a role-stress response, monoamine synthesis, and cognitive functioning-are implicated also in the pathophysiology of major depressive disorder. In search of possible objective biomarkers of depression, the aim of the study was to assess the relationship between osteocalcin and depressive symptoms during the treatment of depressive episode. Methods: The study included female inpatients with at least moderate depressive episode. In these patients, depression severity was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS), and osteocalcin levels were assessed before the stabilization of antidepressive treatment and after 6 weeks. Relationships between osteocalcin levels and symptoms were analyzed with mixed-effect and linear models, taking into account age, menopausal status, and body mass index. Results: In 11 out of 13 enrolled inpatients, osteocalcin levels decreased during the first 6 weeks of treatment; this decrease was significant according to the mixed-effects model (t = -2.345, p = 0.019). According to the linear model, this decrease was significantly associated with reduction in depressive symptom severity (t = 2.673, p = 0.028). Osteocalcin was not associated with initial depressive symptom severity, and initial osteocalcin levels did not predict response to treatment. Limitations of the study include low sample size and inclusion of both pre- and postmenopausal women of various ages. Conclusions: This preliminary study suggests that osteocalcin may be a candidate biomarker of antidepressive treatment response and that this topic warrants further investigation.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hořínková, Jana $u Department of Psychiatry, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia
700    1_
$a Křenek, Pavel $u Department of Psychiatry, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia $7 xx0282289
700    1_
$a Damborská, Alena $u Department of Psychiatry, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia
700    1_
$a Tomandl, Josef $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Tomandlová, Marie $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Kučera, Jan $u RECETOX, Faculty of Science, Masaryk University, Brno, Czechia
700    1_
$a Fialová Kučerová, Jana $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Bienertová-Vašků, Julie $u RECETOX, Faculty of Science, Masaryk University, Brno, Czechia $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia
773    0_
$w MED00174602 $t Frontiers in psychiatry $x 1664-0640 $g Roč. 13, č. - (2022), s. 893012
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35982931 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20230220151542 $b ABA008
999    __
$a ind $b bmc $g 1853939 $s 1174897
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 893012 $e 20220802 $i 1664-0640 $m Frontiers in psychiatry $n Front Psychiatry $x MED00174602
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace